2025年4月2日 周三
Home > Archive>Volume 33, Issue 2, 2025 >154-162. DOI:10. 20039/ j. cnki. 1007-3949. 2025. 02. 009
PDF HTML XML Export Cite reminder
Application of cardiac magnetic resonance T1 mapping in cardiomyopathy and development of imaging technology
Author:
Affiliation:

1.Department of Cardiology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China;2.Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan 421001, China;3.Institute of Cardiovascular Disease, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China;4.Department of Radiology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China;5.Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China)

Clc Number:

R5

  • Article
    • | |
  • Metrics
    • |
  • Reference [73]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    As cardiac magnetic resonance imaging technology advances, T1 mapping has emerged as a non-invasive method offering visual and quantitative insights into myocardial fibrosis, edema, and infiltration associated with cardiac diseases. The application of T1 mapping in myocardial diseases allows for evaluating both focal and diffuse myocardial fibrosis, playing a crucial clinical role in the differentiation, treatment, and prognostic risk assessment of diseases. This article aims to provide a thorough overview of the clinical applications of T1 mapping in patients with cardiomyopathy, summarizing the commonly employed scanning techniques and imaging principles.

    Reference
    [1] CIARAMBINO T, MENNA G, SANSONE G, et al.Cardiomyopathies:an overview.Int J Mol Sci, 1,2(14):7722.
    [2] TAN K, FOO R, LOH M.Cardiomyopathy in Asian cohorts:genetic and epigenetic insights.Circ Genom Precis Med, 3,6(5):496-506.
    [3] MESSROGHLI D R, MOON J C, FERREIRA V M, et al.Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume:a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI).J Cardiovasc Magn Reson, 7,9(1):75.
    [4] 周笛, 赵世华, 陆敏杰.心肌T1-mapping进展:成像技术与临床应用.放射学实践, 0,5(7):933-938.ZHOU D, ZHAO S H, LU M J.Advances in myocardial T1 mapping:imaging techniques and clinical applications.Radiol Prac, 0,5(7):933-938.
    [5] ROBINSON A A, CHOW K, SALERNO M.Myocardial T1 and ECV measurement:underlying concepts and technical considerations.JACC Cardiovasc Imaging, 9,2(11 Pt 2):2332-2344.
    [6] 贾韬宇, 秦培鑫, 扈锋, 等.T1 mapping技术原理及其在心肌定量的研究进展.磁共振成像, 2,3(3):151-158.JIA T Y, QIN P X, HU F, et al.Principle of T1 mapping technique and its research progress in myocardial quantification.Chin J Magn Reson Imag, 2,3(3):151-158.
    [7] KELLMAN P, HANSEN M S.T1-mapping in the heart:accuracy and precision.J Cardiovasc Magn Reson, 4,6(1):2.
    [8] NACIF M S, TURKBEY E B, GAI N, et al.Myocardial T1 mapping with MRI:comparison of look-locker and MOLLI sequences.J Magn Reson Imaging, 1,4(6):1367-1373.
    [9] PIECHNIK S K, FERREIRA V M, DALL'ARMELLINA E, et al.Shortened modified look-locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold.J Cardiovasc Magn Reson, 0,2(1):69.
    [10] HUANG L, NEJI R, NAZIR M S, et al.Fast myocardial T1 mapping using shortened inversion recovery based schemes.J Magn Reson Imaging, 9,0(2):641-654.
    [11] CHOW K, FLEWITT JA, GREEN JD, et al.Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping.Magn Reson Med, 4,1(6):2082-2095.
    [12] ROUJOL S, WEINGRTNER S, FOPPA M, et al.Accuracy, precision, and reproducibility of four T1 mapping sequences:a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE.Radiology, 4,2(3):683-689.
    [13] CHILD N, SUNA G, DABIR D, et al.Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction.Eur Heart J Cardiovasc Imaging, 8,9(7):768-776.
    [14] WEINGRTNER S, AKAKAYA M, BASHA T, et al.Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability.Magn Reson Med, 4,1(3):1024-1034.
    [15] SOHANI M, VAN DER GEEST RJ, MAIER A, et al.Improved cardiac T1 mapping accuracy and precision with a new hybrid MOLLI and SASHA technique:MOSHA.Magn Reson Imaging, 2,9:33-41.
    [16] BENTATOU Z, TROALEN T, BERNARD M, et al.Simultaneous multi-slice T1 mapping using MOLLI with blipped CAIPIRINHA bSSFP.Magn Reson Imaging, 3,5:90-102.
    [17] MARTY B, COPPA B, CARLIER P G.Fast, precise, and accurate myocardial T1 mapping using a radial MOLLI sequence with FLASH readout.Magn Reson Med, 8,9(3):1387-1398.
    [18] KAMMERLANDER AA, MARZLUF BA, ZOTTER-TUFARO C, et al.T1 mapping by CMR imaging:from histological validation to clinical implication.JACC Cardiovasc Imaging, 6,9(1):14-23.
    [19] CHEN B H, WU C W, AN D A, et al.Myocardial extracellular volume quantified by cardiac magnetic resonance predicts left ventricular aneurysm following acute myocardial infarction.Eur Radiol, 3,3(1):283-293.
    [20] TREIBEL T A, FRIDMAN Y, BERING P, et al.Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1.JACC Cardiovasc Imaging, 0,3(1 Pt 1):44-54.
    [21] GAO Y, WANG H P, LIU M X, et al.Early detection of myocardial fibrosis in cardiomyopathy in the absence of late enhancement:role of T1 mapping and extracellular volume analysis.Eur Radiol, 3,3(3):1982-1991.
    [22] NADJIRI J, ZASCHKA A L, STRAETER A S, et al.Evaluation of a shortened cardiac MRI protocol for left ventricular examinations:diagnostic performance of T1-mapping and myocardial function analysis.BMC Med Imaging, 9,9(1):57.
    [23] MCKENNA WJ, MARON BJ, THIENE G.Classification, epidemiology, and global burden of cardiomyopathies.Circ Res, 7,1(7):722-730.
    [24] SEWARD JB, CASACLANG-VERZOSA G.Infiltrative cardiovascular diseases:cardiomyopathies that look alike.J Am Coll Cardiol, 0,5(17):1769-1779.
    [25] KOTTAM A, HANNEMAN K, SCHENONE A, et al.State-of-the-art imaging of infiltrative cardiomyopathies:a scientific statement from the American heart association.Circ Cardiovasc Imaging, 3,6(11):e000081.
    [26] VULLAGANTI S, LEVINE J, RAIKER N, et al.Fibrosis in hypertrophic cardiomyopathy patients with and without sarcomere gene mutations.Heart Lung Circ, 1,0(10):1496-1501.
    [27] MARON BJ, DESAI MY, NISHIMURA RA, et al.Management of hypertrophic cardiomyopathy:JACC state-of-the-art review.J Am Coll Cardiol, 2,9(4):390-414.
    [28] XU J, ZHUANG B Y, SIRAJUDDIN A, et al.MRI T1 mapping in hypertrophic cardiomyopathy:evaluation in patients without late gadolinium enhancement and hemodynamic obstruction.Radiology, 0,4(2):275-286.
    [29] HUANG L, RAN L P, ZHAO P J, et al.MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy:tissue remodeling manifested prior to structure changes.Br J Radiol, 9,2(1104):20190634.
    [30] LI Y C, LIU X M, YANG F Y, et al.Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.Eur Radiol, 1,1(7):4557-4567.
    [31] QIN L, MIN J H, CHEN C H, et al.Incremental values of T1 mapping in the prediction of sudden cardiac death risk in hypertrophic cardiomyopathy:a comparison with two guidelines.Front Cardiovasc Med, 1,8:661673.
    [32] HO CY, ABBASI SA, NEILAN TG, et al.T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.Circ Cardiovasc Imaging, 3,6(3):415-422.
    [33] WIJNKER PJM, VAN DER VELDEN J.Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue.Biochim Biophys Acta Mol Basis Dis, 0,6(8):165774.
    [34] ICHIDA F.Left ventricular noncompaction.Circ J, 9,3(1):19-26.
    [35] ROSS S B, JONES K, BLANCH B, et al.A systematic review and Meta-analysis of the prevalence of left ventricular non-compaction in adults.Eur Heart J, 0,1(14):1428-1436.
    [36] ZHOU D, LI S J, SIRAJUDDIN A, et al.CMR characteristics, gene variants and long-term outcome in patients with left ventricular non-compaction cardiomyopathy.Insights Imaging, 1,2(1):184.
    [37] ARAUJO-FILHO J A B, ASSUNCAO A N J, TAVARES DE MELO M D, et al.Myocardial T1 mapping and extracellular volume quantification in patients with left ventricular non-compaction cardiomyopathy.Eur Heart J Cardiovasc Imaging, 8,9(8):888-895.
    [38] HEYMANS S, LAKDAWALA N K, TSCHPE C, et al.Dilated cardiomyopathy:causes, mechanisms, and current and future treatment approaches.Lancet, 3,2(10406):998-1011.
    [39] NAKAMORI S, DOHI K, ISHIDA M, et al.Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy.JACC Cardiovasc Imaging, 8,1(1):48-59.
    [40] AUS DEM SIEPEN F, BUSS S J, MESSROGHLI D, et al.T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance:quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy.Eur Heart J Cardiovasc Imaging, 5,6(2):210-216.
    [41] LI S, ZHOU D, SIRAJUDDIN A, et al.T1 mapping and extracellular volume fraction in dilated cardiomyopathy:a prognosis study.JACC Cardiovasc Imaging, 2,5(4):578-590.
    [42] PUNTMANN V O, CARR-WHITE G, JABBOUR A, et al.T1-mapping and outcome in nonischemic cardiomyopathy:all-cause mortality and heart failure.JACC Cardiovasc Imaging, 6,9(1):40-50.
    [43] CADOUR F, QUEMENEUR M, BIERE L, et al.Prognostic value of cardiovascular magnetic resonance T1 mapping and extracellular volume fraction in nonischemic dilated cardiomyopathy.J Cardiovasc Magn Reson, 3,5(1):7.
    [44] KIAOS A, ANTONAKAKI D, BAZMPANI M A, et al.Prognostic value of cardiovascular magnetic resonance T1 mapping techniques in non-ischemic dilated cardiomyopathy:a systematic review and Meta-analysis.Int J Cardiol, 0,2:110-116.
    [45] FRIEDRICH M G, SECHTEM U, SCHULZ-MENGER J, et al.Cardiovascular magnetic resonance in myocarditis:a JACC white paper.J Am Coll Cardiol, 9,3(17):1475-1487.
    [46] PAN J A, LEE Y J, SALERNO M.Diagnostic performance of extracellular volume, native T1, and T2 mapping versus lake louise criteria by cardiac magnetic resonance for detection of acute myocarditis:a Meta-analysis.Circ Cardiovasc Imaging, 8,1(7):e007598.
    [47] FERREIRA V M, SCHULZ-MENGER J, HOLMVANG G, et al.Cardiovascular magnetic resonance in nonischemic myocardial inflammation:expert recommendations.J Am Coll Cardiol, 8,2(24):3158-3176.
    [48] RADUNSKI U K, LUND G K, SRING D, et al.T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis.Clin Res Cardiol, 7,6(1):10-17.
    [49] LI H J, ZHU H, YANG Z X, et al.Tissue characterization by mapping and strain cardiac MRI to evaluate myocardial inflammation in fulminant myocarditis.J Magn Reson Imaging, 0,2(3):930-938.
    [50] GARCIA-PAVIA P, RAPEZZI C, ADLER Y, et al.Diagnosis and treatment of cardiac amyloidosis:a position statement of the ESC working group on myocardial and pericardial diseases.Eur Heart J, 1,2(16):1554-1568.
    [51] LI X, HUANG S S, MIAO H L, et al.Multiparameter cardiac magnetic resonance to monitor therapeutic effect after chemotherapy in light chain amyloidosis patients.JACC Cardiovasc Imaging, 1,4(7):1485-1487.
    [52] MARTINEZ-NAHARRO A, PATEL R, KOTECHA T, et al.Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.Eur Heart J, 2,3(45):4722-4735.
    [53] THONGSONGSANG R, SONGSANGJINDA T, TANAPIBUNPON P, et al.Native T1 mapping and extracellular volume fraction for differentiation of myocardial diseases from normal CMR controls in routine clinical practice.BMC Cardiovasc Disord, 1,1(1):270.
    [54] DEL BUONO M G, MORONI F, MONTONE R A, et al.Ischemic cardiomyopathy and heart failure after acute myocardial infarction.Curr Cardiol Rep, 2,4(10):1505-1515.
    [55] 朱慧, 左后娟, 马飞, 等.二维斑点追踪超声心动图评价非缺血性心肌病和缺血性心肌病的左心室功能.中国动脉硬化杂志, 1,9(7):595-599.ZHU H, ZUO H J, MA F, et al.Evaluation of left ventricular function in patients with non-ischemic cardiomyopathy and ischemic cardiomyopathy by two-dimensional speckle tracking echocardiography.Chin J Arterioscler, 1,9(7):595-599.
    [56] EMRICH T, HALFMANN M, SCHOEPF U J, et al.CMR for myocardial characterization in ischemic heart disease:state-of-the-art and future developments.Eur Radiol Exp, 1,5(1):14.
    [57] KIDAMBI A, MOTWANI M, UDDIN A, et al.Myocardial extracellular volume estimation by CMR predicts functional recovery following acute MI.JACC Cardiovasc Imaging, 7,0(9):989-999.
    [58] WANG G, LEE S E, YANG Q, et al.Multicenter study on the diagnostic performance of native-T1 cardiac magnetic resonance of chronic myocardial infarctions at 3T.Circ Cardiovasc Imaging, 0,3(6):e009894.
    [59] SHIN J M, CHOI E Y, PARK C H, et al.Quantitative T1 mapping for detecting microvascular obstruction in reperfused acute myocardial infarction:comparison with late gadolinium enhancement imaging.Korean J Radiol, 0,1(8):978-986.
    [60] NAKAMORI S, ALAKBARLI J, BELLM S, et al.Native T1 value in the remote myocardium is independently associated with left ventricular dysfunction in patients with prior myocardial infarction.J Magn Reson Imaging, 7,6(4):1073-1081.
    [61] PUNTMANN V O, CARR-WHITE G, JABBOUR A, et al.Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease.J Am Coll Cardiol, 8,1(7):766-778.
    [62] YANG M X, HE Y, MA M, et al.Characterization of infarcted myocardium by T1-mapping and its association with left ventricular remodeling.Eur J Radiol, 1,7:109590.
    [63] LYON AR, CITRO R, SCHNEIDER B, et al.Pathophysiology of takotsubo syndrome:JACC state-of-the-art review.J Am Coll Cardiol, 1,7(7):902-921.
    [64] SCALLY C, ABBAS H, AHEARN T, et al.Myocardial and systemic inflammation in acute stress-induced (takotsubo) cardiomyopathy.Circulation, 9,9(13):1581-1592.
    [65] DABIR D, LUETKENS J, KUETTING D L R, et al.Cardiac magnetic resonance including parametric mapping in acute takotsubo syndrome:preliminary findings.Eur J Radiol, 9,3:217-224.
    [66] AIKAWA Y, NOGUCHI T, MORITA Y, et al.Clinical impact of native T1 mapping for detecting myocardial impairment in takotsubo cardiomyopathy.Eur Heart J Cardiovasc Imaging, 9,0(10):1147-1155.
    [67] TAN J L, TAN B E X, CHEUNG J W, et al.Update on cardiac sarcoidosis.Trends Cardiovasc Med, 3,3(7):442-455.
    [68] BIRNIE D H, SAUER W H, BOGUN F, et al.HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.Heart Rhythm, 4,1(7):1305-1323.
    [69] TERASAKI F, AZUMA A, ANZAI T, et al.JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis-digest version.Circ J, 9,3(11):2329-2388.
    [70] KOURANOS V, TZELEPIS G E, RAPTI A, et al.Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis.JACC Cardiovasc Imaging, 7,0(12):1437-1447.
    [71] TREIBER J, NOVAK D, FISCHER-RASOKAT U, et al.Regional extracellular volume within late gadolinium enhancement-positive myocardium to differentiate cardiac sarcoidosis from myocarditis of other etiology:a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson, 3,5(1):8.
    [72] CHEUNG E, AHMAD S, AITKEN M, et al.Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis.Eur J Hybrid Imaging, 1,5(1):24.
    [73] GREULICH S, KITTERER D, LATUS J, et al.Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction.Circ Cardiovasc Imaging, 6,9(11):e005022.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

DENG Jia, TANG Huifang, ZHOU Hong, YU Ying, YANG Wenmin, ZHOU Jinbiao, TIAN Jinwei. Application of cardiac magnetic resonance T1 mapping in cardiomyopathy and development of imaging technology[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2025,33(2):154-162.

Copy
Share
Article Metrics
  • Abstract:23
  • PDF: 389
  • HTML: 0
  • Cited by: 0
History
  • Received:January 17,2024
  • Revised:February 23,2024
  • Online: March 05,2025
Article QR Code

You are the 26274 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025